Results in NVAF Patients With Diabetes Consistent With the Overall Trial
Patients with nonvalvular AF typically have multiple chronic comorbid conditions.*1 XARELTO® has been studied in a large number of these patients in the ROCKET AF trial.2,3
The XARELTO® nonvalvular trial (ROCKET AF) enrolled 14,264 patients with multiple comorbidities†2,3
*Based on 2007 data of 5% sample size of Medicare beneficiaries.
†Percentage of patients calculated by pooling total patients with noted characteristics in each trial arm.
AF = atrial fibrillation; CHF = congestive heart failure; LVEF = left ventricular ejection fraction.
Diabetes and its treatment can complicate stroke risk reduction in nonvalvular AF
The risk of stroke is 1.5x higher in patients with diabetes than in those without4
Life expectancy can be reduced by ~12 years in patients aged 60 years with diabetes and a history of stroke‡5
An anticoagulant that requires multiple pills many times a day may add to the pill burden patients with diabetes already face
- XARELTO® is 1 pill taken once daily
Patients with diabetes may have to watch their diets more closely with the use of warfarin6
- XARELTO® has no known dietary restrictions
‡Based on data from the Emerging Risk Factors Collaboration (689,300 participants) and the UK Biobank (499,808 participants).
Stroke reductions in the high-risk patients with diabetes you see every day (post hoc subgroup analysis)
Patients with diabetes had a mean CHADS2 score of 3.77
§A 19% relative risk reduction (RRR) in stroke or systemic embolism was observed in patients with diabetes receiving XARELTO® (n=95) versus warfarin (n=114), HR (95% CI), 0.81 (0.62-1.07)||
||RRR was calculated using 1 minus the HR.
CHADS2 = CHF, hypertension, age ≥75 years, diabetes mellitus, prior stroke or TIA; HR = hazard ratio.